| 多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗胃癌的疗效比较 |
| |
| 引用本文： | 王勇,李国苗,李志斌,钟世寿. 多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗胃癌的疗效比较[J]. 现代肿瘤医学, 2020, 0(10): 1712-1714. DOI: 10.3969/j.issn.1672-4992.2020.10.023 |
| |
| 作者姓名： | 王勇 李国苗 李志斌 钟世寿 |
| |
| 作者单位： | 内江市第二人民医院，四川 内江 641000 |
| |
| 摘 要： | 目的:比较多西他赛联合氟尿嘧啶、顺铂方案与多西他赛联合氟尿嘧啶、洛铂方案治疗晚期不可手术胃癌患者的疗效和不良反应。方法:回顾性分析2015年2月至2018年6月126例晚期不可手术的胃癌患者。洛铂组55例:多西他赛+氟尿嘧啶+洛铂，顺铂组71例:多西他赛+氟尿嘧啶+顺铂。洛铂组和顺铂组均21天为一个疗程，连续治疗四个疗程。结果:洛铂组患者客观有效率为50.91%，顺铂组为35.21%，差异无统计学意义（P＞0.05）。洛铂组患者疾病控制率达到83.64%，顺铂组为67.61%，差异有统计学意义（P＜0.05）。洛铂组患者在恶心、呕吐、白细胞减少和四肢麻木方面发生率明显低于顺铂组，差异有统计学意义（P＜0.05）。洛铂组患者血小板减少发生率高于顺铂组，差异有统计学意义（P＜0.05）。洛铂组患者严重不良反应的发生率为21.82%，顺铂组为39.44%，差异具有统计学意义（P＜0.05）。结论:将多西他赛联合氟尿嘧啶、顺铂方案中的顺铂以洛铂替代，取得了更好的疾病控制率，而患者的不良反应更轻，严重不良反应的发生率也更低，值得临床进一步研究。
|
| 关 键 词： | 多西他赛 氟尿嘧啶 顺铂 洛铂 胃癌 |
Comparison of efficacy between docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of gastric cancer |
| |
| Wang Yong,Li Guomiao,Li Zhibin,Zhong Shishou. Comparison of efficacy between docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of gastric cancer[J]. Journal of Modern Oncology, 2020, 0(10): 1712-1714. DOI: 10.3969/j.issn.1672-4992.2020.10.023 |
| |
| Authors: | Wang Yong Li Guomiao Li Zhibin Zhong Shishou |
| |
| Affiliation: | The Second People's Hospital of Neijiang，Sichuan Neijiang 641000,China. |
| |
| Abstract: | Objective:To compare the efficacy and side effects of docetaxel+fluorouracil+cisplatin regimen and docetaxel+fluorouracil+lobaplatin regimen in the treatment of advanced non-operative gastric cancer.Methods:From February 2015 to June 2018,126 patients with advanced gastric cancer who were not operable were analyzed retrospectively,including lobaplatin group 55 cases(docetaxel+fluorouracil+lobaplatin)and cisplatin group 71 cases(docetaxel+fluorouracil+cisplatin).The two groups were treated for 21 days for a course of treatment,and continuous treatment for four courses.Results:The objective response rate was 50.91%in lobaplatin group and 35.21%in cisplatin group,with no significant difference(P>0.05).The disease control rate of lobaplatin group was 83.64%,and that of cisplatin group was 67.61%.The difference was statistically significant(P<0.05).The nausea,vomiting,leukopenia and limb numbness in lobaplatin group were significantly less than those in cisplatin group(P<0.05).The incidence of thrombocytopenia in patients with lobaplatin group was higher than that in cisplatin group,and the difference was statistically significant(P<0.05).The incidence of severe adverse reactions was 21.82%in lobaplatin group and 39.44%in cisplatin group(P<0.05).Conclusion:Lobaplatin was used to replace cisplatin in docetaxel+fluorouracil+cisplatin regimen,and the disease control rate was better,and the side effects of patients were lighter,the incidence of serious adverse reactions was lower,which is worthy of further clinical study. |
| |
| Keywords: | docetaxel fluorouracil cisplatin lobaplatin gastric cancer |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
|
